Grace Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2024 · Filed Feb 13, 2025
GRCE$1.86-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
| Common stock | ||||||
|---|---|---|---|---|---|---|
| (Expressed in thousands except share data) | Number | Amount | Additional paid-incapital | Accumulated othercomprehensive loss | Accumulated deficit | Total stockholders' equity |
| $ · $ · $ · $ · $ | ||||||
| Balance, March 31, 2024 | 9,399,404 | 1 | 278,899 | (6,038) | (211,119) | 61,743 |
| Issuance of common stock upon cashless exercise of pre-funded warrants | 740,457 | — | — | — | — | — |
| Net loss and total comprehensive loss for the period | — | — | — | — | (2,617) | (2,617) |
| Stock-based compensation | — | — | 238 | — | — | 238 |
| Balance at June 30, 2024 | 10,139,861 | 1 | 279,137 | (6,038) | (213,736) | 59,364 |
| Net loss and total comprehensive loss for the period | — | — | — | — | (3,432) | (3,432) |
| Stock-based compensation | — | — | 202 | — | — | 202 |
| Balance at September 30, 2024 | 10,139,861 | 1 | 279,339 | (6,038) | (217,168) | 56,134 |
| Net loss and total comprehensive loss for the period | — | — | — | — | (4,155) | (4,155) |
| Stock-based compensation | — | — | 160 | — | — | 160 |
| Balance at December 31, 2024 | 10,139,861 | 1 | 279,499 | (6,038) | (221,323) | 52,139 |
| Common stock | ||||||
|---|---|---|---|---|---|---|
| (Expressed in thousands except share data) | Number | Amount | Additional paid-incapital | Accumulated othercomprehensive loss | Accumulated deficit | Total stockholders' equity |
| $ · $ · $ · $ · $ | ||||||
| Balance, March 31, 2023 | 7,435,533 | 1 | 272,259 | (6,038) | (198,266) | 67,955 |
| Net loss and total comprehensive loss for the period | — | — | — | — | (4,023) | (4,023) |
| Stock-based compensation | — | — | 78 | — | — | 78 |
| Balance at June 30, 2023 | 7,435,533 | 1 | 272,337 | (6,038) | (202,289) | 64,010 |
| Issuance of common stock and pre-funded warrants through private placement, net of offering costs | 1,951,371 | — | 5,707 | — | — | 5,707 |
| Issuance of common stock upon the exercise of stock options | 12,500 | — | 21 | — | — | 21 |
| Net loss and total comprehensive loss for the period | — | — | — | — | (3,273) | (3,273) |
| Stock-based compensation | — | — | 280 | — | — | 280 |
| Balance at September 30, 2023 | 9,399,404 | 1 | 278,344 | (6,038) | (205,562) | 66,745 |
| Net loss and total comprehensive loss for the period | — | — | — | — | (2,391) | (2,391) |
| Stock-based compensation | — | — | 326 | — | — | 326 |
| Balance at December 31, 2023 | 9,399,404 | 1 | 278,670 | (6,038) | (207,953) | 64,680 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.